Herein, we have shown that a dual inhibitor of PDE1B and PDE10A, compound 2, prevented and reversed schizophrenia-like behavioural alterations induced by ketamine, suggesting the potential of compound 2 as a promising therapy for schizophrenia. Here, PDE1B is linked to schizophrenia.